BEL secures manufacturing licence for its RxT17 Haemodialysis machine

Bengaluru: Navratna Defence PSU Bharat Electronics Limited (BEL) has obtained the Licence to Manufacture (for sale/distribution) its indigenously developed Haemodialysis machine — BEL RxT17.

BEL RxT17, designed by M/s Renalyx and to be manufactured by BEL, is one of India’s first indigenous Haemodialysis machines, a significant milestone for India’s Medtech sector.

It is a boon for patients suffering from chronic renal failure, facilitating safe, efficient and high-quality dialysis therapy. The Central Drugs Standard Control Organisation (CDSCO) granted BEL the manufacturing license after the compliance audit for Class C regulatory requirements pertaining to high-risk device safety and performance standards.

BEL RxT17 is CE Certified, confirming compliance with European safety, health and environmental standards, and enabling its global market acceptance.

Driven by a surge in the cases of End-Stage Renal Disease, the demand for dialysis is increasing rapidly in India, and the BEL RxT17 aims to improve accessibility and affordability of dialysis care.

BEL RxT17 features a colour touchscreen display that provides an advanced user interface with real-time information on device status, readings and active alarms.

It is equipped with both audio and visual alarms for critical conditions. The machine is designed to be compatible with all standard pharmacy consumables and disposables, ensuring seamless integration into existing hospital workflows.

Its simple design focuses on ease of maintenance and straightforward operation for healthcare providers.

BEL RxT17 reduces dependence on imported dialysis machines and strengthens India’s domestic Medtech manufacturing ecosystem. It is a step toward building globally competitive, high-quality medical technologies in India, in line with the Government’s Atmanirbhar Bharat initiative.